CLSDQ
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -1.14 | $201,000 | -$5M |
| 2025 Q2 | -0.87 | $492,000 | -$5M |
| 2025 Q1 | -1.60 | $2M | -$6M |
| 2024 Q4 | -1.44 | $306,000 | -$6M |
| 2024 Q3 | -1.54 | $1M | -$6M |
| 2024 Q2 | -1.52 | $90,000 | -$6M |
| 2024 Q1 | -2.53 | $230,000 | -$8M |
| 2023 Q4 | -1.16 | $6M | $375,000 |